P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
Masoom Priyadarshini,
Gaurav Deshpande,
Simran K Tiwana,
T. Kim Le,
Sean Garrison,
Farrukh Awan
Affiliations
Masoom Priyadarshini
1 Bristol Myers Squibb, Princeton, United States
Gaurav Deshpande
1 Bristol Myers Squibb, Princeton, United States
Simran K Tiwana
1 Bristol Myers Squibb, Princeton, United States
T. Kim Le
1 Bristol Myers Squibb, Princeton, United States
Sean Garrison
1 Bristol Myers Squibb, Princeton, United States
Farrukh Awan
2 University of Texas Southwestern Medical Center, Dallas, United States
